A synthetic analogue of growth hormone-releasing hormone, engineered for greater stability than the natural signal. It has no US approval.

What is the difference between CJC-1295 with and without DAC?

The DAC version carries a modification intended to extend how long the molecule persists in the body. The two forms behave differently, and material sold under the bare name may be either.

What are the side effects of CJC-1295?

There is no approved label, so there is no regulator-reviewed account of adverse effects to cite. Anyone presenting a confident profile for a compound without an approval dossier is going beyond the available evidence.

Is CJC-1295 the same as sermorelin?

Both are GHRH analogues, but they are different molecules with different histories — sermorelin held US approval and was withdrawn; CJC-1295 never held one.

CJC-1295

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone. Like sermorelin it acts upstream of growth hormone rather than supplying it, and unlike sermorelin it has never held US approval.

One detail causes more confusion here than anything else: CJC-1295 is discussed in two forms, and people frequently talk past each other because they mean different ones.

TypeGHRH analogue
FormsWith and without DAC
US statusNot FDA-approved
SportWADA-prohibited

What it is

A synthetic GHRH analogue, engineered for greater stability than the natural signal. It is not growth hormone, and it is not a supplement.

Most of what circulates about this compound comes from preclinical work — cell and animal models. What research explores in that setting does not transfer automatically to people, and the gap between a promising animal result and an established human option is where almost all of the marketing in this category lives.

DAC and non-DAC — the distinction that matters

CJC-1295 is discussed in two forms. One carries a drug affinity complex, usually written as DAC, which is a modification intended to extend how long the molecule persists in the body. The other does not, and is often referred to by a different name entirely.

This is not a trivial labelling difference. The two behave differently in the body, and material sold under the bare name CJC-1295 may be either. If you are being offered this, establishing which form is being discussed is the first question, not a detail to sort out later.

How side effects are properly discussed

We are not going to publish a symptom list for an unapproved compound and invite you to self-monitor against it. There is no approved label here, which is precisely the point: an approved medicine comes with a regulator-reviewed account of its adverse effects, and this does not.

What that absence means practically is that nobody — including whoever is selling it — can give you a reliable account of what to expect or how common anything is. Anyone presenting a confident side-effect profile for a compound with no approval dossier is presenting something they do not have.

If a licensed clinician is supervising, they are the person to raise anything with, and they should have told you in advance what they will be monitoring and how often.

Where it comes from, and why that matters

Material sold online is generally offered as a research chemical for laboratory use. That is not a formality. It means the vial was not prepared to pharmaceutical manufacturing standards, was not tested for identity and purity the way a prescription medicine is, and was not intended to be put into a person.

Independent testing of this market has repeatedly found products that do not match their labels — wrong quantity, wrong substance, or contaminants. You cannot assess any of that by looking at the vial.

A compounding pharmacy working on a prescriber's order is a different situation with real oversight attached. If someone is offering you a compounded preparation, ask which pharmacy, in which state, and under what authority for this specific substance.

Where to take this

If growth hormone signalling is genuinely the question, it can be investigated. Ask for that investigation rather than for a compound.

Dosing is determined by a licensed provider.

How we verify providers

Questions

CJC-1295: common questions

What is CJC-1295?: A synthetic analogue of growth hormone-releasing hormone, engineered for greater stability than the natural signal. It has no US approval.
What is the difference between CJC-1295 with and without DAC?: The DAC version carries a modification intended to extend how long the molecule persists in the body. The two forms behave differently, and material sold under the bare name may be either.
What are the side effects of CJC-1295?: There is no approved label, so there is no regulator-reviewed account of adverse effects to cite. Anyone presenting a confident profile for a compound without an approval dossier is going beyond the available evidence.
Is CJC-1295 the same as sermorelin?: Both are GHRH analogues, but they are different molecules with different histories — sermorelin held US approval and was withdrawn; CJC-1295 never held one.

Talk to a licensed provider before considering any of this

Peptides are prescriber territory, and the useful first step is finding out what is actually going on rather than picking a compound. We connect you with licensed providers who investigate first.

Find a licensed provider

TreatRadar is an information and referral service. We are not a medical provider, we do not practise medicine, and nothing here is medical advice, diagnosis, or a treatment recommendation. Decisions about treatment belong to you and a licensed clinician who knows your history.

We may be compensated when you connect with a provider through this site. That never changes which providers we list or how we describe them — how we verify providers.

Some information (pricing, provider coverage, state rules) may change or await verification — confirm details directly with the provider or the relevant state medical board before booking.